We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Alder Biopharmaceuticals Announces Expanded Collaboration with Schering-Plough
News

Alder Biopharmaceuticals Announces Expanded Collaboration with Schering-Plough

Alder Biopharmaceuticals Announces Expanded Collaboration with Schering-Plough
News

Alder Biopharmaceuticals Announces Expanded Collaboration with Schering-Plough

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alder Biopharmaceuticals Announces Expanded Collaboration with Schering-Plough"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Alder Biopharmaceuticals, Inc. has announced the expansion of its collaborative alliance with Schering-Plough Corporation. The collaboration continues to be successful in identifying numerous high quality therapeutic monoclonal antibody lead candidates.

Candidates with potential applications to Central Nervous System (CNS) disorders are being identified through the application of Alder’s high throughput antibody selection (ABS) system and yeast production system (Mab Xpress). These technologies are designed to identify and produce best-in-class antibodies.

Under terms of the agreement, Alder will receive an upfront payment, committed funding for Alder personnel who are engaged in the project and milestone payments associated with the advancement of a therapeutic candidate as well as future product royalties.

“This expanded collaboration further validates the promise and potential of Alder’s leading capabilities to expeditiously identify and manufacture therapeutic monoclonal antibodies,” said Randall Schatzman, Ph.D., Chief Executive Officer of Alder. “We look forward to the continued and expanded partnership with Schering Plough, a leader in therapeutic antibody development and commercialization. More broadly, we are pleased to be positively impacting the way in which companies discover and manufacture biotherapeutics.”
Advertisement